Cns Pharmaceuticals Stock Today

CNSP Stock  USD 0.11  0.01  8.33%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 88

 
High
 
Low
Very High
Cns Pharmaceuticals is selling at 0.11 as of the 3rd of December 2024; that is 8.33 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.11. Cns Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Cns Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of October 2024 and ending today, the 3rd of December 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
8th of November 2019
Category
Healthcare
Classification
Health Care
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company was incorporated in 2017 and is based in Houston, Texas. Cns Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 40.75 M outstanding shares of which 683.26 K shares are currently shorted by private and institutional investors with about 0.04 trading days to cover. More on Cns Pharmaceuticals

Moving together with Cns Stock

  0.61VRAX Virax Biolabs GroupPairCorr
  0.73VRCA Verrica PharmaceuticalsPairCorr

Moving against Cns Stock

  0.67EWTX Edgewise TherapeuticsPairCorr
  0.66ETON Eton PharmaceuticalsPairCorr
  0.64VRNA Verona Pharma PLCPairCorr
  0.6ELDN Eledon Pharmaceuticals Downward RallyPairCorr

Cns Stock Highlights

President CEOJD Esq
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities6.4 M6.1 M
Sufficiently Up
Slightly volatile
Total Assets1.6 M1.7 M
Notably Down
Slightly volatile
Total Current Assets1.5 M1.6 M
Notably Down
Slightly volatile
Debt Levels
Cns Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cns Pharmaceuticals' financial leverage. It provides some insight into what part of Cns Pharmaceuticals' total assets is financed by creditors.
Liquidity
Cns Pharmaceuticals currently holds 300.81 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Cns Pharmaceuticals has a current ratio of 12.09, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Cns Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Total Cash From Operating Activities

(13.43 Million)
Cns Pharmaceuticals (CNSP) is traded on NASDAQ Exchange in USA. It is located in 2100 West Loop South, Houston, TX, United States, 77027 and employs 3 people. Cns Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.28 M. Cns Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 40.75 M outstanding shares of which 683.26 K shares are currently shorted by private and institutional investors with about 0.04 trading days to cover. Cns Pharmaceuticals currently holds about 8.96 M in cash with (14.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cns Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Cns Pharmaceuticals holds a total of 40.75 Million outstanding shares. Almost 98.1 percent of Cns Pharmaceuticals outstanding shares are held by general public with 1.2 (percent) owned by insiders and only 0.7 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cns Ownership Details

Cns Stock Institutional Holders

InstituionRecorded OnShares
Fmr Inc2024-09-30
0.0
Morgan Stanley - Brokerage Accounts2024-09-30
0.0
Vanguard Group Inc2024-06-30
0.0
Anson Funds Management Lp2024-09-30
0.0
Armistice Capital, Llc2024-06-30
0.0
Fsm Wealth Advisors, Llc2024-06-30
0.0
Virtu Financial Llc2024-06-30
0.0
Xtx Topco Ltd2024-06-30
0.0
Two Sigma Securities, Llc2024-06-30
0.0
Geode Capital Management, Llc2024-09-30
203.2 K
Ubs Group Ag2024-09-30
181.9 K
View Cns Pharmaceuticals Diagnostics

Cns Pharmaceuticals Historical Income Statement

At this time, Cns Pharmaceuticals' Interest Expense is relatively stable compared to the past year. As of 12/03/2024, Research Development is likely to grow to about 14.8 M, though Operating Income is likely to grow to (17.9 M). View More Fundamentals

Cns Stock Against Markets

Additional Tools for Cns Stock Analysis

When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.